Allogene Therapeutics, Inc. (NASDAQ:ALLO) is expected to report third quarter earnings results, before market open, on Wednesday 4th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.54 per share.
Looking ahead, the full year loss are expected at $ 2.16 per share.
Stock Performance
Shares of Allogene Therapeutics, Inc. traded up $ 0.54 or 1.62 percent on Tuesday, reaching $ 33.79 with volume of 795.40 thousand shares. Allogene Therapeutics, Inc. has traded high as $ 34.01 and has cracked $ 33.04 on the downward trend
According to the previous trading day, closing price of $ 33.79, representing a 90.76 % increase from the 52 week low of $ 17.43 and a 39.55 % decrease over the 52 week high of $ 55.00.
The company has a market capital of $ 4.71 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Allogene Therapeutics, Inc. will be hosting a conference call at 8:30 AM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.allogene.com
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent.
